IRIS Accounts Production v22.2.0.402 09694988 Board of Directors 1.1.21 31.12.21 31.12.21 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pure096949882020-12-31096949882021-12-31096949882021-01-012021-12-31096949882019-12-31096949882020-01-012020-12-31096949882020-12-3109694988ns16:EnglandWales2021-01-012021-12-3109694988ns15:PoundSterling2021-01-012021-12-3109694988ns11:Director12021-01-012021-12-3109694988ns11:PrivateLimitedCompanyLtd2021-01-012021-12-3109694988ns11:SmallEntities2021-01-012021-12-3109694988ns11:AuditExemptWithAccountantsReport2021-01-012021-12-3109694988ns11:SmallCompaniesRegimeForDirectorsReport2021-01-012021-12-3109694988ns11:SmallCompaniesRegimeForAccounts2021-01-012021-12-3109694988ns11:FullAccounts2021-01-012021-12-310969498812021-01-012021-12-3109694988ns11:Director22021-01-012021-12-3109694988ns11:Director32021-01-012021-12-3109694988ns11:Director42021-01-012021-12-3109694988ns11:Director52021-01-012021-12-3109694988ns11:Director62021-01-012021-12-3109694988ns11:Director72021-01-012021-12-3109694988ns11:Director82021-01-012021-12-3109694988ns11:RegisteredOffice2021-01-012021-12-3109694988ns6:CurrentFinancialInstruments2021-12-3109694988ns6:CurrentFinancialInstruments2020-12-3109694988ns6:ShareCapital2021-12-3109694988ns6:ShareCapital2020-12-3109694988ns6:SharePremium2021-12-3109694988ns6:SharePremium2020-12-3109694988ns6:RetainedEarningsAccumulatedLosses2021-12-3109694988ns6:RetainedEarningsAccumulatedLosses2020-12-3109694988ns6:IntangibleAssetsOtherThanGoodwill2021-01-012021-12-3109694988ns6:PlantMachinery2021-01-012021-12-3109694988ns6:PatentsTrademarksLicencesConcessionsSimilar2020-12-3109694988ns6:PatentsTrademarksLicencesConcessionsSimilar2021-01-012021-12-3109694988ns6:PatentsTrademarksLicencesConcessionsSimilar2021-12-3109694988ns6:PatentsTrademarksLicencesConcessionsSimilar2020-12-3109694988ns6:PlantMachinery2021-12-3109694988ns6:CostValuation2020-12-3109694988ns6:WithinOneYearns6:CurrentFinancialInstruments2021-12-3109694988ns6:WithinOneYearns6:CurrentFinancialInstruments2020-12-31
















Argonaute RNA Limited

Financial Statements for the Year Ended 31 December 2021






Argonaute RNA Limited

Company Information
for the Year Ended 31 December 2021







DIRECTORS: R M Tompkins
D W D Ball
R T Burn
R C Docherty
A M Fink
M M T Khan
J V Matlock
A M Parker





REGISTERED OFFICE: 15 Frederick Place
Bristol
BS8 1AS





REGISTERED NUMBER: 09694988 (England and Wales)





ACCOUNTANTS: BPU Limited
Chartered Accountants
Radnor House
Greenwood Close
Cardiff Gate Business Park
Cardiff
CF23 8AA

Chartered Accountants' Report to the Board of Directors
on the Unaudited Financial Statements of
Argonaute RNA Limited


The following reproduces the text of the report prepared for the directors in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Balance Sheet. Readers are cautioned that the Income Statement and certain other primary statements and the Report of the Directors are not required to be filed with the Registrar of Companies.

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Argonaute RNA Limited for the year ended 31 December 2021 which comprise the Profit & Loss Account, Balance Sheet and the related notes from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed within the ICAEW's regulations and guidance at http://www.icaew.com/en/membership/regulations-standards-and-guidance.

This report is made solely to the Board of Directors of Argonaute RNA Limited, as a body, in accordance with our terms of engagement. Our work has been undertaken solely to prepare for your approval the financial statements of Argonaute RNA Limited and state those matters that we have agreed to state to the Board of Directors of Argonaute RNA Limited, as a body, in this report in accordance with ICAEW Technical Release 07/16AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Argonaute RNA Limited and its Board of Directors, as a body, for our work or for this report.

It is your duty to ensure that Argonaute RNA Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and loss of Argonaute RNA Limited. You consider that Argonaute RNA Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Argonaute RNA Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.






BPU Limited
Chartered Accountants


6 September 2022

Argonaute RNA Limited (Registered number: 09694988)

Balance Sheet
31 December 2021

2021 2020
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 3 75,927 36,508
Tangible assets 4 78,364 -
Investments 5 100 100
154,391 36,608

CURRENT ASSETS
Debtors 6 176,264 54,389
Cash at bank 734,743 57,738
911,007 112,127
CREDITORS
Amounts falling due within one year 7 67,947 44,468
NET CURRENT ASSETS 843,060 67,659
TOTAL ASSETS LESS CURRENT
LIABILITIES

997,451

104,267

CAPITAL AND RESERVES
Called up share capital 187 146
Share premium 1,692,429 279,982
Retained earnings (695,165 ) (175,861 )
997,451 104,267

Argonaute RNA Limited (Registered number: 09694988)

Balance Sheet - continued
31 December 2021


The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2021.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2021 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Profit & Loss Account has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 6 September 2022 and were signed on its behalf by:





R M Tompkins - Director


Argonaute RNA Limited (Registered number: 09694988)

Notes to the Financial Statements
for the Year Ended 31 December 2021


1. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention as modified by the revaluation of certain assets.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition the patents and licences are amortised over the remaining life of the patents once the asset starts to generate revenue.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery - 33% straight line

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Profit & Loss Account, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Pension costs
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

2. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 6 (2020 - 7 ) .

Argonaute RNA Limited (Registered number: 09694988)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2021


3. INTANGIBLE FIXED ASSETS
Patents
and
licences
£   
COST
At 1 January 2021 36,508
Additions 39,419
At 31 December 2021 75,927
NET BOOK VALUE
At 31 December 2021 75,927
At 31 December 2020 36,508

4. TANGIBLE FIXED ASSETS
Plant and
machinery
£   
COST
Additions 90,221
At 31 December 2021 90,221
DEPRECIATION
Charge for year 11,857
At 31 December 2021 11,857
NET BOOK VALUE
At 31 December 2021 78,364

5. FIXED ASSET INVESTMENTS
Own
shares
£   
COST OR VALUATION
At 1 January 2021
and 31 December 2021 100
NET BOOK VALUE
At 31 December 2021 100
At 31 December 2020 100

Argonaute RNA Limited (Registered number: 09694988)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2021


5. FIXED ASSET INVESTMENTS - continued

Cost or valuation at 31 December 2021 is represented by:

Own
shares
£   
Valuation in 100 100

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2021 2020
£    £   
Other debtors & prepayments 176,264 54,389

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2021 2020
£    £   
Trade creditors 53,143 43,618
Taxes & social security costs 13,054 -
Other creditors & accruals 1,750 850
67,947 44,468